Literature DB >> 29529595

RANKL/OPG system regulation by endogenous PTH and PTH1R/ATF4 axis in bone: Implications for bone accrual and strength in growing rats with mild uremia.

Beata Znorko1, Dariusz Pawlak2, Ewa Oksztulska-Kolanek1, Tomasz Domaniewski1, Anna Pryczynicz3, Alicja Roszczenko4, Joanna Rogalska4, Paweł Lipowicz5, Michał Doroszko6, Malgorzata Michalina Brzoska4, Krystyna Pawlak7.   

Abstract

Osteoprotegerin (OPG), receptor activator of NF-κB ligand (RANKL), and parathyroid hormone (PTH) play a central role in the regulation of bone turnover in chronic kidney disease (CKD), but their influence on bone mineral density (BMD) and strength remains unclear, particularly in children. We studied the clinical significance of OPG and RANKL in relation to PTH, femur weight, BMD, and bone biomechanical properties in growing rats after one month (CKD-1) and three months (CKD-3) of surgically-induced mild CKD. Gene expression of parathyroid hormone 1 receptor (PTH1R) and activating transcription factor 4 (ATF4), major regulators of anabolic PTH response in bone, was also determined. Serum PTH and bone PTH1R/ATF4 expression was elevated in CKD-3 compared with other groups, and it positively correlated with femur weight, BMD, and the biomechanical properties of the femoral diaphysis reflecting cortical bone strength. In contrast, bone RANKL/OPG ratios were decreased in CKD-3 rats compared with other groups, and they were inversely correlated with PTH and the other abovementioned bone parameters. However, the PTH-PTH1R-ATF4 axis exerted an unfavorable effect on the biomechanical properties of the femoral neck. In conclusion, this study showed for the first time an inverse association between serum PTH and the bone RANKL/OPG system in growing rats with mild CKD. A decrease in the RANKL/OPG ratio, associated with PTH-dependent activation of the anabolic PTH1R/ATF4 pathway, seems to be responsible for the unexpected, beneficial effect of PTH on cortical bone accrual and strength. Simultaneously, impaired biomechanical properties of the femoral neck were observed, making this bone site more susceptible to fractures.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Growing rats; Mild chronic kidney disease; PTH1R/ATF4 pathway; Parathyroid hormone; RANKL/OPG system

Mesh:

Substances:

Year:  2018        PMID: 29529595     DOI: 10.1016/j.cyto.2018.03.002

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  5 in total

1.  Alleviative Effects of Exercise on Bone Remodeling in Fluorosis Mice.

Authors:  Rui Li; Zeen Gong; Yanghuan Yu; Ruiyan Niu; Shengtai Bian; Zilong Sun
Journal:  Biol Trace Elem Res       Date:  2021-05-03       Impact factor: 3.738

2.  Modulation of the Paracrine Kynurenic System in Bone as a New Regulator of Osteoblastogenesis and Bone Mineral Status in an Animal Model of Chronic Kidney Disease Treated with LP533401.

Authors:  Adrian Mor; Krystyna Pawlak; Bartlomiej Kalaska; Tomasz Domaniewski; Beata Sieklucka; Marta Zieminska; Bogdan Cylwik; Dariusz Pawlak
Journal:  Int J Mol Sci       Date:  2020-08-19       Impact factor: 5.923

3.  Therapeutic Effects of the Proximal Femoral Nail for the Treatment of Unstable Intertrochanteric Fractures.

Authors:  Yuwei Cai; Wenjun Zhu; Nan Wang; Zhongxiang Yu; Yu Chen; Shengming Xu; Juntao Feng
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-02       Impact factor: 2.650

4.  Vitamin K-Dependent Carboxylation of Osteocalcin in Bone-Ally or Adversary of Bone Mineral Status in Rats with Experimental Chronic Kidney Disease?

Authors:  Marta Ziemińska; Dariusz Pawlak; Beata Sieklucka; Katarzyna Chilkiewicz; Krystyna Pawlak
Journal:  Nutrients       Date:  2022-10-01       Impact factor: 6.706

5.  Paracrine Kynurenic Pathway Activation in the Bone of Young Uremic Rats Can Antagonize Anabolic Effects of PTH on Bone Turnover and Strength through the Disruption of PTH-Dependent Molecular Signaling.

Authors:  Krystyna Pawlak; Beata Sieklucka; Dariusz Pawlak
Journal:  Int J Mol Sci       Date:  2021-06-18       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.